Cancer cells often gains a growth advantage by taking up glucose at a high rate and undergoing aerobic glycolysis through intrinsic cellular factors that reprogram glucose metabolism. Focal adhesion kinase (FAK), a key transmitter of growth factor and anchorage stimulation, is aberrantly overexpressed or activated in most solid tumors including pancreatic ductal adenocarcinomas (PDACs). We determined whether FAK can act as an intrinsic driver to promote aerobic glycolysis and tumorigenesis. FAK inhibition decreases and overexpression increases intracellular glucose levels during unfavorable conditions including growth factor deficiency and cell detachment. Amplex glucose assay, fluorescence and carbon-13 tracing studies demonstrate that FAK promotes glucose consumption and glucose-to-lactate conversion. Extracellular flux analysis indicates that FAK enhances glycolysis and decreases mitochondrial respiration. FAK increases key glycolytic proteins including enolase, pyruvate kinase M2 (PKM2), lactate dehydrogenase and monocarboxylate transporter. Furthermore, active/tyrosine-phosphorylated FAK directly binds to PKM2 and promotes PKM2-mediated glycolysis. On the other hand, FAK-decreased levels of mitochondrial complex I can result in reduced oxidative phosphorylation (OXPHOS). Attenuation of FAK-enhanced glycolysis re-sensitizes cancer cells to growth factor withdrawal, decreases cell viability, and reduces growth of tumor xenografts. These observations, for the first time, establish a vital role of FAK in cancer glucose metabolism through alterations in the OXPHOS-toglycolysis balance. Broadly targeting the common phenotype of aerobic glycolysis and more specifically FAK-reprogrammed glucose metabolism will disrupt the bioenergetic and biosynthetic supply for uncontrolled growth of tumors, particularly glycolytic PDAC.
Introduction
Glycolysis maintains energy and carbon supply to meet high metabolic requirements during tumor growth and survival. Pancreatic ductal adenocarcinoma (PDAC) has a strong glycolytic phenotype. 1 Increased intracellular glucose levels have been observed in the majority of solid tumors including PDAC. 2 -4 Based on this unique difference between normal and tumor tissues, attempts have been made to identify oncogenic glucose metabolic pathways and block glucose uptake in cancer cells. However, no effective therapeutic intervention targeting glucose metabolism in malignancy currently exists. An increased understanding of molecular events that are responsible for tumor-specific glucose elevation and usage will allow for effective targeting of glucose metabolism.
A dynamic balance of oxidative phosphorylation and glycolysis is essential for cellular adaptation to microenvironmental changes. Sustained elevation of intracellular glucose may favor the glucose-to-pyruvate reaction in tumor cells. In addition, the well-recognized finding of increased glycolysis in tumor cells results in excessive tumor lactate production. 5 Moreover, the transition from a localized-to-metastatic tumor phenotype is correlated with further increases in lactate efflux rate through overexpression of transporters including monocarboxylate transporter 4 (MCT4). 5 Elevation of glycolysis enzymes and transporters has been identified in various tumor types.
Growth factors including insulin and insulin-like growth factor 1 (IGF-1) stimulate glucose uptake and metabolism through receptor activation of FAK-related downstream signaling. 6 -8 Abnormal hyperactivity of FAK due to gene amplification of FAK-associated signal transduction pathways promotes metabolic activity and proliferation even in the absence of growth factors. This notion is supported by the observation that FAK overexpression contributes to malignant cell glucose, lipid and amino acid metabolism. 9 Although many oncogenes have been reported to modulate mitochondrial respiration, there is a paucity of information regarding a role for FAK in tumor glucose metabolism. A tumor suppressor, BTG2, inhibits tumor cell migration through interrupting mitochondria-related FAK-Src signaling. 10 FAK has been shown to translocate to the nucleus and interact with p53. This observation implies that FAK can serve as a "cortex to nuclear shuttle" to relay growth factor and anchorage stimulation for survival by p53-mediated mitochondrialglycolytic balance. Furthermore, activation of FAK is associated with lactate dehydrogenase (LDH) release in nerve cells. 11 FAK contributes to MCT4-mediated migration and invasion of oral squamous cell carcinoma (SCC). 12 Although these observations imply a correlation between tumor-related FAK overexpression and lactate release, the direct link is still missing.
modulate glucose-to-lactate conversion and efflux? And, 3) what are the key players in FAK modulation of oxidative phosphorylation (OXPHOS) and glycolysis in tumor cells. Our current observations demonstrate, for the first time, that FAK contributes to malignancyrelated glucose elevation and conversion to lactate through direct interaction with key glycolytic proteins and via decreased mitochondrial complex I expression.
Results

Modulation of aberrant glucose elevation in PDAC cells
We analyzed the glucose content in human pancreatic ductal epithelial (HPDE) cells and four human PDAC cell lines. The steady-state levels of glucose in PDAC cells are 7-13 fold higher than that in HPDE ( Fig 1A) . Extracellular glucose is known to affect the levels of intracellular glucose in many cell types. 13 We adjusted the level of glucose in the KSFM medium used for HPDE cells to a similar level as in DMEM (Miapaca-2 cells), i.e. 4.5 g/l.
The glucose levels in Miapaca-2 cells are significantly higher than in HPDE cells, when Miapaca-2 and HPDE are exposed to the same amount of extracellular glucose ( Fig 1B) .
The results demonstrate that PDAC cells retain high levels of intracellular glucose, which is consistent with the phenomena that the majority of solid tumors accumulate intracellular glucose.
Next, we assessed the effects of extracellular stimuli on intracellular glucose levels. Growth factors and anchorage are essential extracellular stimuli to promote glucose metabolism and epithelial growth. Thus, we cultured Miapaca-2 cells on fibronectin-coated or uncoated ultra-low cell binding plate (anchorage) in the presence or absence of serum (growth factors). Interestingly, withdrawal of growth factors, anchorage, or both does not decrease but significantly increases intracellular glucose levels ( Fig 1C) . Therefore, in order to determine the intrinsic control of tumor cell glucose metabolism, most experiments are performed in growth factor and anchorage limited conditions. All values for lactate, glucose, and LDH have been normalized to protein content. The conditions for each experiment are documented in each figure legend.
Since normal (HPDE) and cancer cell lines (Mia, PANC, HS and Apsc-1) are typically cultured in different media (KSFM, DMEM, or RPMI), the levels of FBS, glucose, pyruvate, glutamine and other nutrients vary significantly. In order to examine the intrinsic cellular control of glucose metabolism in normal and PDAC cells, 2-NBDG [2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose, a fluorescent glucose analog] was used to assess glucose influx under identical conditions, i.e. basic medium (DMEM) in the absence of FBS, pyruvate, and glutamine. PDAC-related glucose elevation is modulated by intrinsic factors but not nutrients (Fig 1D) . The data supports the notion that oncogenic glucose elevation in PDAC cells is primarily controlled by intracellular or intrinsic factors.
examined whether glucose elevation in PDAC correlates with increased FAK expression. The level of FAK protein in Miapaca-2 cells was significantly higher than that in normal cells (Fig 2A) . This suggests that FAK elevation is associated with increased levels of glucose in PDAC cells.
Next, we elucidated the role of FAK in oncogenic glucose elevation using specific gene manipulation. To establish the link between FAK and intrinsic tumor cell glucose elevation, we suppressed FAK expression in tumor cells using siRNA. Inhibition of FAK expression decreased glucose levels under stimulus-limited conditions (0.5% FBS and uncoated plates) (Fig 2B) . To rule out the possibility that transfection-associated cell injury may contribute to the decreased glucose levels, we stably transfected Miapaca-2 cells with constructs expressing GFP or mCherry-tagged N-terminal FAK (CNTF), the F1 subdomain of FAK. F1 binding to Y397 is known to prevent FAK activation/phosphorylation and Src recruitment. 14 Interestingly, ectopic overexpression of the FAK F1 subdomain in Miapaca-2 cells decreases the levels of FAK protein (insets of Fig 2C) , suggesting that the F1 subdomain can act as a dominant-negative (DN) form of FAK. F1 inhibition of FAK leads to decreased levels of intrinsic glucose under extracellular stimulation-limited conditions ( Fig  2C) . Inhibition of FAK expression using siRNA or F1 techniques may have off-target effects on other signaling pathways. To overcome this obstacle, we delivered the vectors expressing FAK or GFP to FAK knockout (KO) SCC cells. The level of glucose in FAK-transfected cells is significantly higher than that in GFP-transfected cells (Fig 2D) , demonstrating a direct effect of FAK on glucose elevation. Finally, we determined whether FAK contributes to oncogenic glucose elevation in addition to normal glucose levels by transfecting HPDE cells with FAK or GFP vectors. Ectopic expression of FAK induces a dramatic increase in the glucose level in HPDE cells, compared to the GFP-transfected cells (Fig 2E) . These observations clearly demonstrate that FAK modulates intrinsic glucose elevation in PDAC cells.
FAK promotes glucose consumption
A possible advantage of PDAC cells maintaining intracellular glucose at a high level is to accelerate the use of glucose. To assess the utilization of glucose, we analyzed glucose content in cell-conditioned and non-conditioned medium under identical conditions. The relative levels of glucose consumed by FAK KO SCC cells are significantly lower than that by the cells expressing wild-type (WT) FAK (Fig 3A) . Furthermore, ectopic overexpression of FAK in HPDE cells promotes glucose consumption (Fig 3B) , suggesting that FAK elevation can contribute to excessive utilization of glucose. Next, we determined whether interruption of the FAK gene in fibroblasts, normal cells with high metabolic activity, could reduce glucose consumption. We cultured FAK KO and WT FAK MEFs in DMEM medium for 48 hr. The relative level of glucose consumed by WT FAK MEFs is higher than that by FAK KO MEFs (Fig 3C) , indicating that FAK is associated with glucose utilization in metabolically active cells.
Many factors such as the rates of uptake, influx, and metabolism affect the steady-state levels of intracellular glucose. However, increased uptake is essential for rapidly growing cells to fuel excessive glucose utilization. We utilized a fluorescent-tagged sugar, 2-NBDG, to trace glucose influx. Interruption of the FAK gene in MEFs leads to a shift of fluorescence intensity to left (KO cells, the red line), i.e. lower levels of 2-NBDG, compared to WT FAK cells (the black line), demonstrating FAK-increased glucose influx (insets in Fig  3D) . The relative level of 2-NBDG accumulating in FAK KO MEFs is significantly lower than that in the cells expressing WT FAK (Fig 3D) . To elucidate the role of PDACassociated FAK elevation in glucose influx, we have disrupted FAK gene expression in Miapaca-2 cells using the CRISPR-Cas9 genome editing system for FAK (Genecopoeia). 15 This is an all-in-one vector containing CRISPR Cas9 nuclease, one CRISPR sgRNA, the neo gene for G418 selection, and mCherry as a fluorescent reporter. Genome average copy numbers are often increased in tumor cells (https://cansar.icr.ac.uk; canSAR, Cancer Research UK). Transfection of PDAC cells (Miapaca-2) with CRISPR-Cas9 FAK constructs (CR-FAK) decreases but does not completely eliminate FAK expression (insets, Fig 3E) . Nevertheless, reduction in FAK gene copies in the transfected PDAC cells decreases 2-NBDG uptake (Fig 3E) . Furthermore, FAK expression in the CRISPRCas9-transfected Miapaca-2 cells has been restored through delivery of pcFAK (FAK, a construct of mCherrytagged FAK) or pGFP (GFP, vehicle). Restoring FAK expression increases 2-NBDG uptake in Miapaca-2 cells (Fig 3F) .
The glucose transporter (Glut1) contributes to the low level basal glucose uptake that sustains respiration in all cells. To examine the effects of FAK on Glut1 expression, the levels of Glut1 protein in Miapaca-2 cells expressing GFP (control) or CNTF (the FAK F1 subdomain) were assessed. The relative level of Glut1 in CNTF-transfected Miapaca-2 cells is lower than that in GFP-transfected cells (Fig 3G) . Furthermore, CRISPR-Cas9 vectordisrupted FAK gene leads to decreased levels of Glut1 protein in Miapaca-2 cells (Fig 3H) .
To restore FAK expression, we have transfected FAK KO SCC cells with pGFP or pcFAK constructs. The level of Glut1 protein in FAK-reinstated cells (FAK) is higher than that in vehicle-transfected cells (GFP, Fig 3I) . These results suggest that FAK-increased Glut1 levels can contribute to elevation of glucose uptake.
Our studies on FAK gene manipulation and glucose analysis demonstrate that FAK can promote glucose utilization, which is associated with increased glucose influx. This can provide a carbon source to fuel uncontrolled cancer cell proliferation under growth factor and/or anchorage stimulation-limited conditions.
FAK increases lactate production
FAK-induced fast turnover of glucose may lead to rapid pyruvate-to-lactate conversion. We assessed the amount of lactate released per hour to the medium by normal and PDAC cells. Cell homogenates as well as medium conditioned with HPDE and Miapaca-2 cells were subjected to de-proteinization and lactate analysis. Indeed, Miapaca-2 cells secrete significantly more lactate into medium than the HPDE cells (Fig 4A) . Interestingly, the level of intracellular lactate in Miapaca-2 cells is also higher than in HPDE cells (Fig 4B) . Lactate derived from glycolysis can be converted back to pyruvate for the TCA cycle. When mitochondrial respiration is limited to processing excessive pyruvate, intracellular lactate levels can be increased causing feedback inhibition of glycolysis. Cellular lactate secretion can remove the feedback inhibition of glycolysis. Increases in intracellular lactate levels (L) and lactate release to the medium (M) suggest enhanced lactate metabolism in Miapaca-2 cells.
Next, we elucidated the role of FAK in aberrant lactate elevation. The level of lactate released into the medium conditioned with Miapaca-2 cells treated with the FAK kinase inhibitor, PF4554878, is significantly lower than that in DMSO-treated cells (Fig 4C) . PF4554878 or defactinib is a potent and specific inhibitor of FAK currently being studied in a variety of solid tumors in clinical trials (https://clinicaltrials.gov/). 16 This drug has been shown to inhibit FAK activity in the low nanomolar range. 16 Secondly, CRISPR-Cas9 disruption of the FAK gene in Miapaca-2 cells leads to reduced lactate release, and restoration of FAK expression in the CRISPR-Cas9-trasnfected cells increases lactate release (Fig 4D) . In addition, CRISPR-Cas9 disruption of the FAK gene reduces the level of intracellular lactate ( Fig 4E, Fig 4I) .
Carbon-13 ( 13 C) labeling and magnetic resonance (NMR) analysis were performed to evaluate the role of FAK in glucose-to-lactate conversion. Miapaca-2 cells expressing the GFP (control) or the CNTF (the FAK F1 subdomain) gene were incubated in medium containing 4.5 g/l 13 C-glucose. The levels of 13 C lactate and 13 C glucose in the cellconditioned medium were subjected to 1 H NMR analysis, and the ratios of lactate/glucose levels relative to the internal standard were calculated. A known pattern of 13 C-related split peaks of 1 H lactate is observed in the NMR profile (upper panel J). The ratio of lactate/ glucose in control Miapaca-2 cell-conditioned medium (GFP) is higher than that in FAK deficient cell-conditioned medium (CNTF) (Fig 4J) . This demonstrates that FAK contributes to glucose-to-lactate conversion in Miapaca-2 cells since a lower ratio in CNTF cellconditioned medium indicates that less 13 C glucose is converted into lactate. To directly examine the effects of FAK on glucose-to-lactate conversion, 13 C NMR was performed to assess the 13 C lactate and glucose levels (upper panel K). CNTF inhibition of FAK in Miapaca-2 cells decreased the ratios of lactate/glucose (Fig 4K) , indicating a role of FAK in glucose-to-lactate conversion. These observations support a vital role of FAK in modulation of glucose-to-lactate conversion in PDAC cells, indicating accelerated glycolysis.
FAK-enhanced glycolysis is associated with increases in key regulatory proteins
Glucose can be processed via two major pathways: glycolysis (acidification) and OXPHOS (oxygen consumption). To monitor FAK-modulated lactate efflux, we performed Extracellular Flux Analysis (Seahorse Bioscience) on stably transfected Miapaca-2 cells expressing GFP or CNTF to assess extracellular acidification rate (ECAR, Fig 5A) . Basal glycolysis is decreased in cells expressing CNTF. On the other hand, CNTF cells display a significant increase in glycolytic reserve capacity, which is calculated as the difference between Oligomycin A induced ECAR and basal ECAR ( Fig 5B) . This suggests that WT (high FAK) Miapaca-2 cells undergo glycolytic flux closer to their maximal rate compared to cells that express CNTF.
To define the molecular events that lead to FAK-enhanced glycolysis, we performed Western blot analysis and observed increases in several key regulatory proteins related to lactate production and transportation. CNTF suppression of FAK expression leads to decreased levels of enolase (ENO) in Miapaca-2 cells (the left panel, Fig 5C) . Furthermore, CRISPRCas9 disruption of the FAK gene in Miapaca-2 cells decreases ENO protein levels (the right panel, Fig 5C) . These observations suggest that aberrant conversion of 2-phosphoglycerate to phosphoenolpyruvate contributes to the glycolytic phenotype of PDAC. Indeed, high levels of enolase protein have been detected in samples from PDAC patients and cell lines.
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PKM2, converting phosphoenolpyruvate into pyruvate, is overexpressed in PDAC. 1 CNTF inhibition of FAK reduces PKM2 levels in Miapaca-2 cells (the left panel, Fig 5D) . Furthermore, ectopic expression of mCherry-tagged FAK (FAK) in FAK KO SCC cells increases PKM2 levels (the right panel, Fig 5D) . The data support the notion that FAK modulates PKM2.
Pyruvate can be converted into lactate by LDH, an enzyme often overexpressed or hyperactivated in PDAC. 18 CNTF inhibition of FAK decreases LDH levels in Miapaca-2 cells (the left panel, Fig 5E) , and ectopic expression of FAK increases LDH levels in FAK KO SCC cells (the right panel, Fig 5E) , indicating a correlation between FAK overexpression and LDH elevation. To verify the specificity of FAK-increased LDH activity, FAK expression was restored in FAK KO SCC cells, resulting in significantly enhanced LDH activity (Fig 5F) . In addition, disruption of the FAK gene in MEFs significantly decreased LDH activity ( Fig 5G) . The results suggest that FAK contributes to LDH hyperactivity.
Lactate transported by MCT protein across the cell membrane sustains fast turnover of glucose-to-lactate, and MCT is involved in tumorigenicity. 5 , 12 We elucidated the role of FAK in modulation of MCT expression. The relative levels of MCT1 protein in Miapaca-2 cells are higher than that in HPDE cells (the left panel, Fig 5H) . Miapaca-2 cells expressing CNTF have less MCT1 protein than cells overexpressing GFP or FAK (the middle panel, Fig  5H) . Furthermore, CRISPR-Cas9 interruption of the FAK gene in Miapaca-2 cells decreases MCT1 protein levels (the right panel, Fig 5H) . Ectopic expression of FAK in CRISPR-Cas9-transfected cells leads to increased levels of MCT1 (the right panel, Fig 5H) . FAK-increased MCT1 mass can increase the capacity of lactate flux during the high turnover of glucose to lactate in Miapaca-2 cells.
FAK interacts with PKM2
PKM2 is exclusively re-expressed in malignancies and promotes incorporation of glucose metabolites into macromolecules rather than burning metabolites to produce CO 2 . Recently, it has been shown that the phosphotyrosine-binding function of PKM2 is required for cancer cell growth. 19 PKM2 binding with phosphotyrosine peptides via K433 disassociates its tetramers to form pro-glycolytic monomers/dimers. 19 Sequence analysis of the FAK peptide reveals a putative PKM2 binding motif (DDY 397 A) within the kinase active site of FAK, which is identical to the residues located at the −2, −1, and +1 position of tyrosine within the optimal PKM2 binding peptide (P-M2tide). 19 Our IP/Western studies suggest that PKM2
can bind to active FAK in vitro (Fig 6A & 6B) . Y397 phosphorylation indicates FAK activation. Indeed, the level of phospho-FAK at Y397 in Miapaca-2 cells was significantly higher than that in normal cells (Fig 6C) .
Next, we determined whether tyrosine phosphorylation of FAK enhances FAK binding with PKM2. IP/Western (Fig 6D) and ELISA (Fig 6E) studies demonstrate that stimulation of Miapaca-2 cells with a potent phosphotyrosine phosphatase inhibitor (pervanadate) enhances FAK phosphorylation and interaction with PKM2. In addition, mutated FAK Y397A retains less PKM2 than WT FAK (Fig 6F) . This suggests that Y397 contributes to FAK binding to PKM2. Furthermore, immobilized recombinant FAK binds with purified PKM2 in a dose dependent manner (Fig 6G) . Anti-phosphotyrosine antibody mimics and phosphotyrosine-BSA inhibits PKM2 interaction with FAK, indicating that tyrosine phosphorylation enhances PKM2 binding with FAK ( Fig 6G) . The results demonstrate that active FAK directly binds to PKM2, which can contribute to FAK-enhanced aerobic glycolysis through modulation of the key regulatory protein, PKM2.
FAK inhibition of mitochondrial respiration through altered complex I subunits
Extracellular flux analysis was performed to assess oxygen consumption rate (OCR). Decreased levels of FAK protein in CNTF-transfected cells results in a significantly increased basal OCR, ATP dependent OCR (difference between basal OCR and oligomycin A inhibited OCR) and maximal FCCP induced OCR, relative to pGFP-transfected Miapaca-2 cells (Fig 7A & 7B) . The results demonstrate that FAK overexpression can suppress mitochondrial respiration in Miapaca-2 cells.
The Mito-tracker green fluorescence probe, which is membrane potential sensitive, was used to examine the distribution of functional mitochondria in live cells. A widely distributed network of mitochondria is observed in HPDE cells, whereas mitochondria are located around nuclei in Miapaca-2 cells (Supplemental Figure 1A) . The FAK inhibitor, PF-4554878, extends the mitochondrial network (insets, Fig 7C) and increases the level of active mitochondria in Miapaca-2 cells (Fig 7C) . To elucidate the role of FAK in cellular mitochondrial distribution, we examined the patterns in WT, FAK KO, and FAKreintroduced MEFs. The mitochondrial network in FAK KO MEFs spreads more to the cell edge compared to WT FAK MEFs (the first and second images of Supplemental Figure 1B ). Ectopic overexpression of FAK in FAK KO cells induces shrinkage of the mitochondrial network (the third image of Supplemental Figure 1B ). In addition, CNTF inhibition of FAK promotes extension of the mitochondrial network (Supplemental Figure 1C ). These observations demonstrate that FAK can modulate the pattern of mitochondrial distribution, which can impact mitochondrial function and contribute to FAK-decreased oxygen consumption.
Mitochondrial complex I is the first enzyme of the electric transport chain and involved in tumorigenicity. 20 We determined whether FAK can modulate the protein levels of complex I subunits NDUFA9 and NDUFB8. FAK elevation in Miapaca-2 cells is negatively correlated with NDUFA9 and NDUFB8 mass, compared to HPDE cells (Fig 7D) . Interruption of the FAK gene in MEFs leads to increased levels of NDUFA9 and NDUFB8 proteins (Fig 7E) .
To verify FAK-decreased complex I subunit levels in tumor cells, WT and FAK KO SCC cell lysates (40, 20 and 10 μg protein/lane) were loaded and show that disrupted FAK gene expression increases NDUFA9 and B8 levels ( Fig 7F) . Next, we examined FAK modulation of complex I subunit expression in PDAC cells. CNTF inhibition of FAK increases NDUFA9 and NDUFB8 levels (Fig 7G) . The band intensity of NDUFA9 in FAK deficient Miapaca-2 cells (CNTF-transfected) is much high than WT cells (Fig 7H) . Furthermore, we used the CRISPR-Cas9 genome editing technique to disrupt the FAK gene in Miapaca-2 cells. FAK deficiency results in increases in both NDUFA9 and NDUFB8 protein mass in PDAC cells (Fig 7I) . The results indicate that FAK can decrease complex I subunit levels. These findings are consistent with our analysis of mitochondrial function, i.e. downregulation of FAK expression leads to increased oxygen consumption.
FAK suppression restores the dependency of PDAC cells on growth factors and reduces tumorigenicity and tumor glycolytic proteins
Malignant cell elevation of FAK expression can maintain cell viability through intrinsic induction of glucose metabolism to compensate for the lack of anchorage and growth factorstimulated glucose uptake. We determined whether suppressed FAK expression could restore the dependency of PDAC cells on growth factor stimulation. Miapaca-2 cells expressing the GFP or CNTF gene were cultured in medium containing 0-10% FBS for 24 hr and subjected to cell viability assay. The relative cell viability of CNTF-transfected Miapaca-2 cells is dependent on FBS doses; whereas FBS levels have minimal impact on GFP-transfected PDAC cells (Fig 8A) . The KRAS gene is mutated in nearly all PDAC samples, 21 , 22 and FAK is required for KRAS-driven tumorigenicity. 23 A colon cancer cell line with well characterized KRAS codon 12 mutation, HCT116, was stably transfected with the CNTF or GFP gene, cultured in medium containing 0-10% FBS, and subjected to cell viability assay. CNTF inhibition of FAK resensitizes KRAS-mutated HCT116 cells to growth factor stimulation ( Fig 8A) .
Following stable disruption of FAK expression, apoptosis and cell viability are unaltered when cells are cultured in normal media with full serum. In addition, apoptosis is slightly, but not significantly increased in FAK deficient Miapaca-2 cells grown in growth factor and anchorage limited conditions and stably transfected with CRISPR-Cas9 FAK constructs (relative levels of DNA fragmentation: 2.79 ± 0.06), as compared to controls (2.49 ± 0.18, p=0.19). However, in the growth factor and anchorage limited conditions, cell viability is significantly reduced following CRISPR-Cas9 FAK gene disruption and improved with FAK restoration as shown in Figure 8B . These are expected results as FAK depletion in anchorage limited conditions has been shown to result in reduced tumor cell growth. 24 -26 To determine whether FAK modulates glycolysis and tumorigenicity in vivo, we implanted GFP-or CNTF-transfected tumor cells into the right (GFP) and left (CNTF) mouse axilla, respectively. The protein levels of key glycolytic proteins including ENO1, PKM2, LDH, MCT1 and MCT4 in CNTF-transfected xenografts (FAK deficient) are lower than those in GFP-transfected cells (Fig 8C) . This suggests that FAK contributes to enhanced tumor glycolysis in vivo. The growth of tumors derived from GFP-transfected HCT116 cells is much faster than that from CNTF-transfected cells (Fig 8D) . The weights (Fig 8E) and sizes (Fig 8F) of isolated tumors derived from GFP-transfected HCT116 cells is dramatically heavier and larger than that from CNTF-transfected cells, respectively. This demonstrates that FAK modulation of intrinsic glucose metabolism plays a key role in tumorigenicity.
These observations support the notion that FAK can act as an intrinsic factor to promote cell growth in a growth factor-independent manner through increased glycolysis and decreased OXPHOS (Fig 8G) .
Discussion
Modulation of glucose elevation in PDAC cells
Our results demonstrate that PDAC-related intracellular glucose elevation is mediated through an intrinsic cellular factor. This notion is supported by the observation that changing extracellular glucose and stimulation (growth factors and extracellular matrix) does not lead to normalization of tumor cell glucose elevation. When normal and PDAC cells are cultured in their optimal medium, intracellular glucose levels in tumor cells are about 7 to 13-fold higher than that in normal cells. The glucose levels in Miapaca-2 cells are still twice that in normal cells, when they are exposed to the same levels of extracellular glucose. This is in line with the observation that intracellular glucose accumulates in colorectal tumors in vivo. 4 In addition, culturing Miapaca-2 cells under conditions with minimal growth and anchorage stimulation does not decrease intracellular glucose levels, indicating intrinsic factor control of glucose levels in Miapaca-2 cells.
FAK regulation of intracellular glucose levels
FAK is well accepted for its role in cell attachment and motility, which demands fast ATP turnover through glucose metabolism. Our data demonstrate that FAK overexpression increases intracellular glucose levels. In addition, transient and stable transfection, gene knockout, and restoration of FAK expression in fibroblasts, SCC cancer cells as well as normal pancreatic ductal and PDAC cells allows us to establish a key link between FAK control of intrinsic glucose elevation. FAK-increased intracellular glucose is associated with high glucose consumption and uptake in PDAC cells. FAK regulation of glucose transport activity has been observed in other types of cells. 27 , 28 Rapid glucose influx can support enhanced glucose metabolism and retention of high levels of intracellular glucose. This may favor increased glycolysis in PDAC cells, which can fuel cell growth and accounts for the phenomenon that FAK elevation is common in localized and metastatic PDAC. 29 , 30 High levels of extracellular glucose can enhance FAK activity or phosphorylation. 31 Those observations support a role of FAK in the cell responding to extracellular glucose stimulation in normal cells. Aberrant activation of FAK through mechanisms including gainof-function mutation such as KRAS mutation or amplification of oncogenes can mimic extracellular glucose stimulation and retain intracellular glucose at high levels in PDAC cells. Indeed, the intracellular glucose levels in Miapaca-2 cells are higher than that in normal cells. 
FAK enhancement of glycolysis and inhibition of OXPHOS
FAK-altered levels of lactate biosynthesis and mitochondrial respiration proteins
FAK overexpression in PDAC cells enhances lactate production through alterations of factors including ENO, PKM2, LDH, and MCT1, which are responsible for pyruvate-tolactate conversion and lactate transport. ENO1 is overexpressed and phosphorylated in PDAC cells 32 , 33 and has been shown to be an important prognostic factor for survival in patients with pancreatic cancer. 17 It has been reported that FAK-related signaling pathways contribute to LDH expression in endothelial cells. 34 Integrin-FAK signaling can contribute to MCT4-modulated migration and invasion of oral SCC.
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PKM2 binding to phosphotyrosine proteins is essential for cell transformation and growth through alterations of PKM2 conformation and activity. Interestingly, the residues of the FAK active site match the optimal PKM2 binding peptide that has been reported to trigger PKM2 conformation changes as well as promote glycolysis and proliferation. 19 IP/Western blot, ELISA with purified proteins, mutagenesis of FAK Y397 and phosphotyrosine phosphatase inhibition studies demonstrate that FAK directly interacts with PKM2. Therefore, FAK activation via Y397 phosphorylation can promote PKM2-increased glycolysis to fuel cancer proliferation. In addition, the phosphotyrosine peptides containing the in vivo SRC kinase site on ENO1 and LDH can bind to and alter PKM2 conformation. 19 Thus, FAK-modulated LDH and ENO1 levels can contribute to PKM2-promoted glycolysis in tumor cells.
FAK expression is negatively correlated with the levels of complex I subunits, which is associated with alteration of mitochondrial distribution and mass. This can contribute to FAK-decreased oxygen consumption in PDAC cells. On the other hand, FAK has been reported to modulate mitochondrial levels in muscle cells that predominantly rely on OXPHOS for ATP production. For example, it has been reported that FAK interacts with mitochondrial transcriptional regulators and enhances stretch-induced mitochondrial biogenesis. 35 Swelled mitochondria in the myocardium of FAK KO mice imply a role of FAK in control of mitochondrial morphology and distribution. 36 FAK downregulation of complex I expression can contribute to the glycolytic phenotype of PDAC cells.
Summary and prospective view
Our current work demonstrates that pro-oncogenic FAK contributes to intrinsic glucose elevation in PDAC cells by shifting the OXPHOS-to-glycolysis balance (Fig 8G) . The mechanism of action is likely in part due to direct binding of FAK to PKM2. Furthermore, FAK-promoted glycolysis and suppressed mitochondrial function are associated with increased ENO1, PKM2, LDH, and MCT mass and decreased mitochondrial complex I subunit expression. Aberrant FAK expression can sustain glucose metabolism to support tumor cell growth during growth suppressing conditions such as lack of growth factors. Disruption of FAK function restores the dependency of tumor cells on growth factors and reduces tumorigenicity. We speculate that small molecules targeting FAK control of tumor metabolism and survival and specifically the interaction of FAK and PKM2 may prevent growth and/or migration of PDAC, particularly malignancies with a glycolytic signature.
Materials and methods
Cell lines and reagents
Human PDAC cell lines (Miapaca-2, Panc-1, HS766T and Aspc-1 were obtained from the ATCC (Manassas, VA) and tested for mycoplasma contamination. HPDE cells were provided by Dr. Otay (University of North Carolina). WT FAK and FAK KO mouse squamous cell carcinoma cells were provided by Prof. Margaret Frame 26 . Recombinant full length FAK and the FAK FERM domain were purchased from Life Technologies (NY, USA) and Blue Sky Biotech (MA, USA), respectively. Recombinant FAK FERM-Y307A protein (Y397 substituted with alanine, A397) was provided by Tim Marlowe (Roswell Park Cancer Institute). Anti-ENO1 (#3810), anti-PKM2 (#4053), anti-FAK (clone 4.47, #05-537) and anti-phosphor-Y397 FAK (#3283) antibodies were from Millipore (MA, USA) or Cell Signaling Technologies (MA, USA). The antibodies recognizing GAPDH (#398600), the subunits of mitochondrial complex I, NDUFA9 (#459100) and NDUFB8 (#459210), were from Life Technologies (NY, USA). The antibodies recognizing LDH (SC-33781), glucose transporter 1 (Glut 1, SC-7903), lactate transporters, MCT1 (SC-365501) and MCT4 (SC-50329) were from Santa Cruz Biotechnology (CA, USA). An anti-β-actin (A5441) antibody was from Sigma (MO, USA). Glucose, lactate, and LDH assay kits were from Life Technologies and Sigma, respectively. WST-1 was from Roche (NY, USA). Chemical reagents were from Fisher Scientific (PA, USA). A specific FAK inhibitor, PF4554878, was provided by Pfizer (CT, USA).
Vector construction and expression
The mCherry-tagged FAK (pcFAK) was obtained from Addgene (MA, USA). The expression vector of the FAK subdomain (F1, amino acids: 1-126) was obtained by restriction enzyme cleavage between Eco RI and Not I, blunting ends and re-ligation of the rescued pcFAK to form the vector of pCNTF. Cells were transfected with pGFP, pcFAK, or pCNTF and selected/maintained by culturing the transfected cells in the medium containing G418. CRISPRCas9 FAK constructs were purchased from GeneCopoeia (MD, USA).
Glucose assay
HPDE, Miapaca-2, PANC-1, HS766T, and Aspc-1 were cultured on a fibronectin-coated or non-coated low-cell binding 6-well plate in KSFM, DMEM, or RPMI 1640 medium in the presence or absence of 10% FBS for 24-48 hr. Medium and attached cells were harvested and subjected to Amplex Red glucose assay (Life Technologies, NY, USA). The protein levels in cell lysates were determined using BCA Protein Assay kit (Pierce, IL, USA). The amounts of glucose that were consumed by the cells were calculated by subtracting the amount of glucose in cell-conditioned medium from that of the medium without cell conditioning. Glucose levels were normalized to cellular protein levels and expressed as μg glucose/mg protein, i.e. the amount of glucose utilized by cells defined per amount of protein mass.
Immunoprecipitation (IP)/Western blot analysis
Full-length FAK (2 ng/μl, #PV3832, Life Technologies, USA) and active PKM2 (6 ng/μl, #6372, BioVision, CA, USA) in the binding buffer (0.05% BSA, 5 mM DTT, 0.05% Triton X100 and 1x PBS, pH 6.5) were mixed and incubated at 4°C for 1 hr. Then, anti-PKM2 antibody (#4053, Cell Signaling Biotechnology, MA, USA) or anti-FAK4.47 was added to the mixture and incubated at 4°C for 2 h. In addition, AG-agarose plus was added, and the mixture was incubated at 4°C overnight.
Immunoprecipitates or cell lysates in NP-40 lysis buffer containing protease and phosphoratease inhibitor cocktails (Roche, USA) were loaded, and gels run as previously described. 30 , 37 Band intensities were quantified using Image-J software (NIH) and normalized to the levels of total FAK, GAPDH or β-actin intensity.
Glucose uptake assay
Cells were cultured in medium containing 0.5% FBS for 48 hr. Then, 5 μl of 2-NBDG (20 mM) was added to 1 ml of medium (final 2-NBDG concentration: 100 μM) and kept for 2 hr. Cells were detached from plates using Accutase (Fisher Scientific, USA), washed, and resuspended in 0.5 ml of PBS. Flowcytometry was performed on the Fortessa instrument. The representative histogram and the mean fluorescence intensity of 2-NBDG in the gated cells are shown. To determine glucose uptake that is specifically driven by intrinsic factors, cells on low cell binding wells were cultured in basic DMEM medium containing 100 μM 2-NBDG without FBS, glucose, pyruvate, and glutamine for 2 hr. The cells were rinsed in PBS and homogenized in lactate assay buffer. Fluorescence intensity and protein levels of cellular homogenates were determined.
Lactate assay
Cells on fibronectin-coated or no-coated plates were kept in stimulus-limited medium (0.5% FBS) for 48 hr. Medium and lysates derived from attached cells were collected and deproteinized with a 10 kDa MWCO spin filter to remove LDH. The lactate levels in medium and deproteinized cell lysates were measured using a lactate assay kit (Sigma).
Protein levels in the lysates that were retained on the filter were analyzed. The lactate levels were determined from the standard curve and normalized to the total cellular protein levels.
Carbon tracing and NMR analysis
GFP-or CNTF-transfected Miapaca-2 cells were kept in medium containing 4.5 g/l of 13 Clabeled glucose for 48 hr. The lactate in conditioned medium was extracted using perchloric acid (0.9M). The extracts were neutralized using KOH, freeze-dried, and dissolved in 0.8 ml of D 2 O. Proton ( 1 H) and 13 C nuclear NMR were performed to determine lactate and glucose levels [The NMR Spectroscopy Facility, Roswell Park Cancer Institute (RPCI)]. Ethylene glycol was used as an internal standard to calculate the relative levels of lactate and glucose. The ratios of lactate/glucose were calculated for the assessments of glucose-to-lactate conversion.
Extracellular flux analysis of glycolysis and mitochondrial function
Seahorse XF24 3 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) was used to assess the live cell OCR, an indicator of mitochondrial respiration; and the ECAR, an indicator of net proton loss during glycolysis. Cells (40,000 cells/well; optimized cell seeding number) were kept on the XF24 culture plate containing XF media (Seahorese Bioscience) in a non-CO 2 37°C incubator for 1 hr prior to OCR and ECAR measurements. Each measurement was taken for a 3 minute period, followed by 3 min mixing and re-oxygenation of the media. Three basal rate measurements were taken prior to injection of pharmacological manipulators of mitochondrial respiratory chain protein (Mitochondrial stress test). Following the establishment of basal OCR and ECAR readings, Oligomycin A (1μM) was injected to inhibit ATP synthase. Maximal respiration was achieved by exposing cells to the mitochondrial uncoupler carbonyl cyanideptrifluoromethoxyphenyl hydrazone (FCCP; 300nM). Antimycin A (1μM) was added to prevent all mitochondria-dependent OCR, by inhibition of mitochondrial complex III. Each cell line was represented in at least 4 wells per experiment and replicate experiments carried out at least three times. ECAR and OCR values were normalized against total protein per well. Basal mitochondrial OCR was derived by subtracting the third OCR reading from that following Antimycin A addition. Respiratory reserve capacity was calculated as the difference between maximal FCCP induced OCR and basal OCR. Glycolytic reserve was determined as the difference between Oligomycin A stimulated ECAR and basal ECAR.
LDH activity assay
Cells were cultured on fibronectin-coated or non-coated plates and kept in stimulus-limited medium (0.5% FBS) for 24-48 hr. Protein and lactate levels of cell lysates were determined using a LDH activity assay kit (Sigma). Serial measurements were made every 5 min. The changes from initial to final readings were used to calculate the amount of NADH generated by LDH in the samples. LDH activity was reported as nmole/min/ml/mg protein or milliunit (mU)/ml/mg. One unit of LDH activity was defined as the amount of enzyme that catalyzes the conversion of lactate into pyruvate to generate 1 μmole of NADH per minute at 37°C.
ELISA assay of FAK-PKM2 interaction
Full-length FAK (0.25 ng/μl in PBS, pH 7.4, #PV3832, Life Technologies, USA) or purified FAK FERM domain (amino acids 31-405) was immobilized on the wells of 8-well Immuno Module (MaxiSorp, #468667, Fisher Scientific, PA, USA) at 4°C overnight. The FAKcoated wells were rinsed with PBS (pH 6.5) and blocked with 10% BSA. Recombinant PKM2 (0-200 nM, #6372, BioVision, CA, USA) in the binding buffer containing 0.05% BSA, 5 mM DTT, 0.05% Triton X100 and 1× PBS, pH 6.5 was added to the FAK-coated wells and incubated at room temperature for 2 hr. Immunodetection was performed using an anti-PKM2 antibody (1:1000, #4053, Cell Signaling Biotechnology, MA, USA) in the buffer containing 20% Super Blocker and 1× PBS (pH 7.4), an anti-rabbit IgG secondary antibody (1:3000), and BM Blue POD Substrate (Roche, IN, USA).
Cell viability assay
pGFP-, pCNTF FAK-, pCRISPR-Cas9-, or pcFAK-transfected cancer cells were cultured on the wells containing 0-10% FBS for 24 hr. WST-1 was added to the wells. The 96-well plate was kept in a 37°C incubator for 10-30 min, and then the absorbance at 450 nm wave length was determined on a microplate reader. 
Xenograft mouse models
Statistical analysis
For in vitro and in vivo studies, the number of biological replicates was calculated using a statistical analysis for power determination. For all studies, we set an alpha value of 0.05, a power of 0.8, and a standard deviation of 0.25. For in vivo studies, we utilized the parameter of a 50% reduction in tumor volume to be considered a significant clinical response. For such studies, six-week-old female SCID mice were randomly assigned to experimental groups. Control and treated-tumor cells were injected into the right (GFP/control) and left (treatment/CNTF) axilla of the same mouse, respectively.
Statistical analysis was performed with one-way ANOVA (2 or more groups) and student's t test (2 groups) using the GraphPad Prism 6 software. The variance was similar between the groups that were statistically compared. Significance was defined as p<0.05. Data are shown as mean with the standard error of the mean (SEM), and images are representative of at least three biological replicates.
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